Stockscreener 앱 받기
0.4169
1.77%
-0.0075
시간 외 거래:
.41
-0.0069
-1.66%
전일 마감가:
$0.4244
열려 있는:
$0.4229
하루 거래량:
376.16K
Relative Volume:
0.64
시가총액:
$25.18M
수익:
$2.29M
순이익/손실:
$-18.63M
주가수익비율:
-0.7419
EPS:
-0.5619
순현금흐름:
$-19.32M
1주 성능:
-3.09%
1개월 성능:
-25.21%
6개월 성능:
-34.72%
1년 성능:
-65.26%
1일 변동 폭
$0.41
$0.4343
1주일 범위
$0.41
$0.438
52주 변동 폭
$0.3067
$1.29
Femasys Inc Stock (FEMY) Company Profile
명칭
Femasys Inc
전화
770-500-3910
주소
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.4169 | 25.63M | 2.29M | -18.63M | -19.32M | -0.5619 |
ISRG
Intuitive Surgical Inc
|
451.29 | 165.37B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.69 | 45.13B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
47.51 | 39.17B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
77.82 | 39.14B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
221.22 | 32.94B | 5.40B | 1.49B | 1.78B | 10.12 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | Laidlaw | Buy |
Femasys Inc 주식(FEMY)의 최신 뉴스
Femasys partners with AMI Technologies for Israel market entry By Investing.com - Investing.com India
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio - Sahm
Femasys (FEMY) Forms Partnership with AMI Technologies to Expand Fertility Portfolio - GuruFocus
Femasys partners with AMI Technologies for Israel market entry - Investing.com
Femasys Enters into A Strategic Partnership with Ami Technologies - marketscreener.com
Weekly Trades: Is Femasys Inc stock undervalued right now2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale - MSN
Market Rankings: Can Femasys Inc sustain its profitabilityBond Market & Fast Moving Stock Trade Plans - baoquankhu1.vn
Femasys (NASDAQ: FEMY) targets reverse split and dilutive note, warrant share issuances - Stock Titan
Can Femasys Inc grow without external funding2026 Closing Moves & Advanced Technical Signal Analysis - baoquankhu1.vn
Femasys appoints John Canning as COO - MSN
Femasys Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Femasys names John Canning as chief operating officer By Investing.com - Investing.com South Africa
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
FEMASYS (FEMY) COO awarded 150,000 stock options at $0.38 exercise price - Stock Titan
Femasys (FEMY) COO John Canning discloses ownership of 30,000 shares - Stock Titan
Femasys Names John Canning as New Chief Operating Officer - TipRanks
Femasys Inc. Appoints John Canning as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth - bitget.com
Femasys names John Canning as chief operating officer - Investing.com
Femasys names John Canning as Chief Operating Officer - TradingView
Veteran MedTech leader John Canning joins Femasys (NASDAQ: FEMY) as COO - Stock Titan
Femasys earnings beat by $0.12, revenue fell short of estimates - ca.investing.com
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - National Today
Femasys 2025 10-K: Revenue $2.29M, Net loss per share $(0.47) - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) advances FemBloc and FemaSeed women’s health platform - Stock Titan
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Femasys 2025 sales jump on FemBloc demand - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) details 2025 results and FemBloc FINALE trial - Stock Titan
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
John Charles Canning Net Worth (2026) - GuruFocus
FEMY Should I Buy - Intellectia AI
Femasys (FEMY) price target decreased by 17.74% to 4.34 - MSN
Femasys (FEMY) CFO receives 34,122 Series D-1 warrants at $0.58 - Stock Titan
Femasys (NASDAQ: FEMY) director awarded 34,122 Series D-1 warrants - Stock Titan
Board seeks reverse split, Nasdaq‑rule approval for issuances (FEMY) - Stock Titan
Femasys (FEMY) CEO receives 68,244 Series D-1 warrants at $0.58 strike - Stock Titan
Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan
Femasys Inc. Enters Omnibus Amendment and Issues Series D-1 Warrants – SEC 8-K Filing March 2026 - Minichart
Femasys amends warrants and notes, appoints new director to board By Investing.com - Investing.com India
Femasys amends warrants and notes, appoints new director to board - Investing.com
Femasys (NASDAQ: FEMY) director receives stock options for 35,200 shares - Stock Titan
Femasys Amends Financing Terms and Issues New Warrants - TipRanks
Femasys enters omnibus amendment and consent agreement on March 19, 2026SEC filing - MarketScreener
Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026SEC Filing - TradingView
Femasys Amends Notes and Warrants; Issues 16.38M New Warrants at $0.58 to Holders - TradingView
Femasys (FEMY) grants 16.4M Series D-1 warrants and appoints new independent director - Stock Titan
Femasys Inc. announced that it has received $12 million in funding - marketscreener.com
Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com South Africa
Femasys Inc (FEMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.86%
1.85%
자본화:
|
볼륨(24시간):